期刊
CELL REPORTS
卷 5, 期 2, 页码 323-330出版社
CELL PRESS
DOI: 10.1016/j.celrep.2013.09.004
关键词
-
类别
资金
- ERC [281648, 250219]
- NIH [AI40696, AI078897, AI069259]
- Italian Association for Cancer Research (AIRC) [9965]
- Giovanni Armenise-Harvard Foundation
- European Research Council (ERC) [250219, 281648] Funding Source: European Research Council (ERC)
Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant-like activity in the absence of CD4(+) and gamma delta T cells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll-like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据